Bimatoprost STADA

What Is Bimatoprost STADA and What Is It Used For?

Bimatoprost STADA is a prescription eye drop containing bimatoprost 0.1 mg/ml, a synthetic prostamide analogue used to reduce elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension. It belongs to the prostaglandin analogue class, which is considered first-line therapy for glaucoma treatment worldwide.

Glaucoma is one of the leading causes of irreversible blindness globally, affecting an estimated 80 million people worldwide according to the World Health Organization. The disease is characterised by progressive damage to the optic nerve, which is often (but not always) associated with elevated intraocular pressure. Open-angle glaucoma, the most common form, develops gradually and often without noticeable symptoms until significant vision loss has occurred.

Bimatoprost STADA works by mimicking the effects of naturally occurring prostamides in the body. The active substance, bimatoprost, increases the outflow of aqueous humour (the clear fluid inside the eye) through two pathways: the trabecular meshwork and the uveoscleral route. By enhancing fluid drainage from the eye, bimatoprost effectively lowers the pressure inside the eye. This reduction in intraocular pressure helps to slow the progression of optic nerve damage and preserve vision.

Ocular hypertension is a related condition in which the pressure inside the eye is elevated above the normal range (typically above 21 mmHg) but where no optic nerve damage has yet occurred. Patients with ocular hypertension are at increased risk of developing glaucoma, and treatment with IOP-lowering medications such as bimatoprost may be recommended to reduce this risk, particularly in individuals with additional risk factors such as thin corneas, a family history of glaucoma, or advanced age.

Bimatoprost STADA is a generic formulation manufactured by STADA Arzneimittel AG and contains the same active ingredient as the original branded product. Generic eye drops undergo rigorous regulatory assessment by the European Medicines Agency (EMA) to ensure they meet the same quality, safety, and efficacy standards as the originator medicine. The 0.1 mg/ml concentration used in Bimatoprost STADA has been shown in clinical trials to provide equivalent IOP-lowering efficacy to the 0.3 mg/ml formulation, while offering a potentially improved tolerability profile with fewer ocular surface side effects.

What Should You Know Before Taking Bimatoprost STADA?

Before using Bimatoprost STADA, inform your doctor about any eye conditions, allergies, pregnancy or breastfeeding status, and all other medications you use. Bimatoprost can cause irreversible changes to eye colour and eyelash appearance, and special precautions apply to certain patient groups.

Contraindications

Bimatoprost STADA should not be used if you are allergic (hypersensitive) to bimatoprost or any of the other ingredients in the formulation. The excipients include benzalkonium chloride (a preservative), sodium chloride, citric acid monohydrate, disodium hydrogen phosphate heptahydrate, hydrochloric acid or sodium hydroxide (for pH adjustment), and purified water. If you have previously experienced an allergic reaction to any prostaglandin analogue eye drop, tell your doctor before starting treatment.

There are no absolute contraindications other than known hypersensitivity. However, bimatoprost should be used with caution in several patient groups. Patients with active intraocular inflammation (e.g., uveitis or iritis) should exercise caution, as prostaglandin analogues may exacerbate inflammatory eye conditions. Similarly, patients with risk factors for cystoid macular oedema, such as those who have undergone recent cataract surgery or who have a history of macular oedema, should be monitored carefully during treatment.

Warnings and Precautions

Before starting treatment with Bimatoprost STADA, you should be aware of several important precautions that apply to this medication. Your prescribing ophthalmologist will discuss these with you, but understanding them thoroughly helps ensure safe and effective use of the medicine.

Iris colour change: Bimatoprost may gradually increase the brown pigmentation of the iris. This occurs because the active substance stimulates melanin production within the melanocytes of the iris. The change in colour is most likely to be noticed in patients with mixed-colour irises (e.g., blue-brown, grey-brown, yellow-brown, or green-brown). In patients with uniformly dark brown eyes, the change may not be readily apparent. Importantly, this iris colour change may be permanent and does not reverse after discontinuation of the medicine. If only one eye is treated, there is a risk of permanent heterochromia (different-coloured eyes).

Periorbital changes: Prostaglandin analogues, including bimatoprost, have been associated with periorbital and eyelid skin darkening, which may be reversible after discontinuation. Additionally, bimatoprost may cause changes in eyelash growth, including increased length, thickness, pigmentation, and number of eyelashes, as well as misdirected growth of eyelashes. Some patients may also develop deepening of the upper eyelid sulcus (a sunken appearance of the upper eyelid), which is generally mild and may be partially reversible upon stopping treatment.

Benzalkonium chloride: Bimatoprost STADA contains benzalkonium chloride as a preservative. This substance may cause eye irritation, especially with prolonged use, and has been shown to discolour soft contact lenses. Contact lenses should be removed before instillation and may be reinserted 15 minutes after application. Patients who wear contact lenses should be monitored regularly for signs of ocular surface disease. In patients with dry eye disease or compromised corneas, benzalkonium chloride may contribute to further corneal damage.

Eye conditions requiring caution: Use bimatoprost with caution if you have active intraocular inflammation (uveitis), aphakia (absence of the natural lens), pseudophakia with a torn posterior lens capsule, or known risk factors for macular oedema. Bimatoprost has not been studied in patients with severe or uncontrolled asthma, and caution is advised in these patients as prostaglandin analogues may theoretically worsen bronchospasm, although systemic absorption from eye drops is minimal.

Pregnancy and Breastfeeding

Bimatoprost STADA should not be used during pregnancy unless clearly necessary and the potential benefit outweighs the potential risk to the foetus. There are no adequate and well-controlled studies of bimatoprost in pregnant women. Animal reproduction studies have shown adverse effects at doses significantly higher than those used clinically, including early resorptions and reduced foetal body weights in rats and mice at intravenous doses that are substantially above the maximum intended human ophthalmic dose.

Women of childbearing potential should use effective contraception during treatment with bimatoprost. If pregnancy occurs during treatment, or if pregnancy is planned, the patient should discuss the risks and benefits of continued treatment with her ophthalmologist.

It is not known whether bimatoprost or its metabolites are excreted in human breast milk. Studies in rats have shown that bimatoprost is excreted in breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue the medicine, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.

How Does Bimatoprost STADA Interact with Other Drugs?

Bimatoprost STADA has relatively few systemic drug interactions due to its topical ophthalmic administration. However, interactions with other eye drops and certain systemic medications should be considered. Always inform your doctor about all medications you are using, including other eye drops.

Because bimatoprost is applied topically to the eye and systemic absorption is minimal, the potential for systemic drug interactions is low. However, certain interactions at the ocular level are clinically relevant and should be discussed with your healthcare provider.

Major Interactions

Other prostaglandin analogues: Bimatoprost should not be used concomitantly with other prostaglandin analogue eye drops (such as latanoprost, travoprost, or tafluprost). Using two prostaglandin analogues simultaneously does not provide additional IOP-lowering benefit and may paradoxically increase intraocular pressure. The combination also increases the risk of ocular side effects, including increased iris pigmentation and periorbital changes.

Thimerosal-containing eye drops: If bimatoprost is used concurrently with eye drops containing thimerosal, the drops should be administered at least 5 minutes apart. Precipitation may occur if they are applied simultaneously, which can reduce the effectiveness of both medications and cause eye irritation.

Minor Interactions

In clinical studies, bimatoprost has been safely used in combination with timolol eye drops (a beta-blocker commonly used for glaucoma). Fixed-dose combinations of bimatoprost and timolol are available and widely used when additional IOP lowering is needed beyond what monotherapy provides. Bimatoprost can also be used alongside other classes of glaucoma medications, including carbonic anhydrase inhibitors (such as dorzolamide or brinzolamide) and alpha-adrenergic agonists (such as brimonidine), provided that at least 5 minutes are allowed between the application of different eye drops.

No formal interaction studies have been conducted with systemic medications. However, given the minimal systemic absorption of topical bimatoprost (peak plasma concentrations of approximately 0.08 ng/ml), clinically significant interactions with systemic drugs are considered unlikely. Nevertheless, patients using systemic prostaglandin inhibitors (such as non-steroidal anti-inflammatory drugs) should inform their ophthalmologist, although no clinically significant interaction has been documented.

What Is the Correct Dosage of Bimatoprost STADA?

The recommended dose of Bimatoprost STADA is one drop in the affected eye(s) once daily, applied in the evening. More frequent application is not recommended as it may reduce the IOP-lowering efficacy. Proper instillation technique, including punctal occlusion, is essential for optimal results.

Adults

The standard recommended dose for adults is one drop of Bimatoprost STADA 0.1 mg/ml instilled into the conjunctival sac of the affected eye(s) once daily. The drop should be administered in the evening, as clinical studies have shown that evening dosing provides optimal 24-hour IOP control. The peak IOP-lowering effect of bimatoprost occurs approximately 8-12 hours after administration, which means that evening dosing results in the greatest pressure reduction during the morning hours, when IOP is typically at its highest.

It is important not to exceed the recommended dose of one drop per day. Paradoxically, more frequent application of bimatoprost (e.g., twice daily) has been shown to be less effective at lowering IOP than once-daily dosing. This may be due to receptor desensitisation when the drug is applied too frequently. If you miss a dose, apply the next dose at the regular time the following evening; do not apply a double dose to make up for the missed one.

Children

The safety and efficacy of Bimatoprost STADA in children and adolescents under 18 years of age have not been established. Bimatoprost is generally not recommended for use in the paediatric population. In cases where glaucoma treatment is needed in children, the ophthalmologist will select the most appropriate medication based on the child's age, the type of glaucoma, and the available clinical evidence.

Elderly

No dose adjustment is necessary for elderly patients. Bimatoprost has been extensively studied in older adults, who constitute the majority of glaucoma patients, and no age-related differences in safety or efficacy have been identified. However, elderly patients may have concurrent dry eye disease or reduced tear production, which could potentially be exacerbated by the benzalkonium chloride preservative. Regular monitoring of the ocular surface is recommended in these patients.

Missed Dose

If you forget to apply your evening dose of Bimatoprost STADA, skip the missed dose and apply your next dose at the usual time the following evening. Do not apply a double dose or an extra drop to compensate for the missed dose. Missing a single dose is unlikely to have a significant impact on your IOP control, but consistently missing doses will reduce the effectiveness of the treatment. If you frequently forget your evening drops, consider setting a daily reminder alarm or associating the drops with another regular evening activity, such as brushing your teeth.

Overdose

If too many drops are accidentally applied to the eye, the most likely effects are eye irritation and conjunctival or episcleral hyperaemia (redness). These effects are transient and typically resolve without intervention. The eye should be rinsed with clean water or sterile saline if multiple drops have been instilled.

Accidental oral ingestion of bimatoprost eye drops is unlikely to cause serious harm due to the small volume in the bottle. However, if accidental ingestion occurs, treatment is supportive and symptomatic. Based on the pharmacological profile of bimatoprost, potential symptoms of systemic overdose could theoretically include flushing, decreased blood pressure, and bronchospasm, although no cases of significant systemic toxicity from oral ingestion of bimatoprost eye drops have been reported. If accidental ingestion occurs, contact your doctor or poison control centre.

What Are the Side Effects of Bimatoprost STADA?

Like all medicines, Bimatoprost STADA can cause side effects, although not everybody gets them. The most common side effects are eye redness (conjunctival hyperaemia), eye pruritus (itching), and eyelash growth. Long-term use may cause permanent iris colour darkening. Most ocular side effects are mild and do not require discontinuation of treatment.

Side effects from bimatoprost eye drops are predominantly localised to the eye and periorbital region. Systemic side effects are rare due to the low systemic absorption of the topically applied drug. The side effect profile of the 0.1 mg/ml formulation has been shown in clinical trials to be generally more favourable than the 0.3 mg/ml formulation, with a lower incidence of conjunctival hyperaemia and other ocular surface adverse events.

It is important to distinguish between side effects that are transient and resolve with continued use and those that may be permanent. Eye redness and irritation typically diminish over the first few weeks of treatment as the eye adapts to the medication. However, changes to iris colour and periorbital skin pigmentation may be permanent even after stopping the drug.

If you experience any severe side effects, sudden vision changes, significant eye pain, or signs of an allergic reaction (swelling, rash, difficulty breathing), stop using Bimatoprost STADA and seek immediate medical attention. For mild side effects that are bothersome or persistent, consult your ophthalmologist, who can advise on whether to continue, adjust, or switch treatment.

How Should You Use Bimatoprost STADA Eye Drops?

Proper instillation technique is essential for maximising the efficacy and minimising the side effects of Bimatoprost STADA. Apply one drop to the affected eye(s) in the evening, use punctal occlusion, and carefully wipe away any excess solution from the skin around the eye.

The correct application technique for Bimatoprost STADA eye drops is crucial for effective treatment. Improper application can lead to reduced efficacy, increased side effects (particularly periorbital skin darkening and eyelash changes), or contamination of the eye drop solution. Follow these steps carefully each time you apply your drops:

1. Wash your hands thoroughly with soap and water before handling the eye drop bottle.
2. Remove contact lenses if you wear them. Wait at least 15 minutes after applying the drops before reinserting lenses.
3. Tilt your head back and look up at the ceiling. Using a clean finger, gently pull down the lower eyelid to create a small pocket (conjunctival sac).
4. Hold the dropper tip close to your eye without touching the eye, eyelid, or any other surface. Squeeze one drop into the pocket formed by the lower eyelid.
5. Close your eye gently (do not squeeze it shut) and immediately press your finger against the inner corner of the eye (near the nose) for 1-2 minutes. This punctal occlusion technique prevents the drop from draining into the nasolacrimal duct and being absorbed systemically.
6. Wipe away any excess solution from the skin around the eye with a clean tissue. This is important to reduce the risk of periorbital skin darkening and unwanted eyelash growth on the surrounding skin.
7. Replace the cap on the bottle immediately after use. Do not touch the dropper tip to any surface.

If you are using other eye drops in addition to Bimatoprost STADA, wait at least 5 minutes between applying different eye drops. This interval ensures that the first drop is properly absorbed and not washed away by the second drop. If you are using both eye drops and an eye ointment, apply the drops first, wait at least 5 minutes, and then apply the ointment last.

How Should You Store Bimatoprost STADA?

Store Bimatoprost STADA below 25°C. After opening, the bottle may be used for up to 4 weeks. Do not freeze. Keep out of the reach and sight of children.

Proper storage of Bimatoprost STADA is essential to maintain the sterility and effectiveness of the eye drop solution. The medication contains benzalkonium chloride as a preservative, which helps prevent microbial contamination, but proper storage practices further reduce the risk of contamination and ensure the drug remains effective throughout its shelf life.

Store the unopened bottle below 25°C. Do not freeze the solution. Keep the bottle in the original carton to protect it from light. Once the bottle has been opened, the solution must be used within 4 weeks. After this period, discard any remaining solution, even if the bottle is not empty, because the preservative system may no longer adequately prevent microbial growth in an opened container.

Do not use Bimatoprost STADA after the expiry date printed on the bottle and carton (marked "EXP"). The expiry date refers to the last day of that month. If you notice that the solution has become discoloured, cloudy, or contains visible particles, do not use it and obtain a new bottle from your pharmacy.

Do not throw away medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment and prevent accidental exposure.

What Does Bimatoprost STADA Contain?

Each millilitre of Bimatoprost STADA contains 0.1 mg of the active substance bimatoprost, along with excipients including benzalkonium chloride (preservative), sodium chloride, and buffering agents.

The active substance in Bimatoprost STADA is bimatoprost. Each millilitre of eye drop solution contains 0.1 mg of bimatoprost (0.01% w/v). Bimatoprost is a synthetic structural analogue of prostamide F2-alpha, a naturally occurring substance in the body. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide, and it has a molecular weight of 415.57 daltons.

The other ingredients (excipients) are:

• Benzalkonium chloride (0.05 mg/ml) – a preservative that prevents microbial contamination. May cause eye irritation and discolour soft contact lenses.
• Sodium chloride – used to adjust the tonicity (osmolarity) of the solution to match the natural tear film.
• Citric acid monohydrate – a buffering agent that helps maintain the pH of the solution.
• Disodium hydrogen phosphate heptahydrate – a buffering agent that works in conjunction with citric acid to maintain stable pH.
• Hydrochloric acid and/or sodium hydroxide – used for final pH adjustment to ensure the solution is well tolerated by the eye.
• Purified water – the solvent base for the solution.

Bimatoprost STADA is available as a clear, colourless to slightly yellow solution in a white opaque plastic dropper bottle. The bottle is fitted with a controlled-drop dispenser tip that delivers approximately 30 microlitres per drop. Each bottle typically contains 3 ml of solution.